4//SEC Filing
Davis Robert M 4
Accession 0001127602-24-005191
CIK 0000310158other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 4:01 PM ET
Size
20.8 KB
Accession
0001127602-24-005191
Insider Transaction Report
Form 4
Davis Robert M
DirectorChairman, CEO & President
Transactions
- Exercise/Conversion
Common Stock
2024-02-13$75.36/sh+41,509$3,128,118→ 389,835.757 total - Exercise/Conversion
Common Stock
2024-02-13$73.73/sh+108,491$7,999,041→ 498,326.757 total - Sale
Common Stock
2024-02-13$125.74/sh−124,676$15,677,147→ 373,650.757 total - Sale
Common Stock
2024-02-13$126.37/sh−25,324$3,200,277→ 348,326.757 total - Exercise/Conversion
Common Stock
2024-02-14$73.73/sh+85,021$6,268,598→ 433,347.757 total - Sale
Common Stock
2024-02-14$125.40/sh−85,021$10,661,574→ 348,326.757 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-13−41,509→ 83,020 totalExercise: $75.36From: 2021-05-01Exp: 2030-04-30→ Common Stock (41,509 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-13−108,491→ 181,781 totalExercise: $73.73From: 2022-05-04Exp: 2031-05-03→ Common Stock (108,491 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-14−85,021→ 96,760 totalExercise: $73.73From: 2022-05-04Exp: 2031-05-03→ Common Stock (85,021 underlying)
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.2700 to $126.2600, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.2650 to $126.525, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.0900 to $125.8200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
- [F5]The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
- [F6]The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.
Documents
Issuer
Merck & Co., Inc.
CIK 0000310158
Entity typeother
Related Parties
1- filerCIK 0001363076
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 4:01 PM ET
- Size
- 20.8 KB